20th Nov 2020 19:26
Genedrive PLC - Manchester-based molecular diagnostics firm - Notes publication of study data for the 'Evaluation of the Point of Care Molecular Diagnostic Genedrive HCV ID Kit for the detection of HCV RNA in clinical samples'.
Study revealed that the kit was suitable for use in India and cane be used for the decentralised testing of seropositive hepatitis C virus.
"These excellent clinical results for our HCV assay further validate the applicability of the test for a decentralised setting. India is a key target market for our assay and we are excited about the commercial prospects in the region," said Chief Executive Officer David Budd.
Current stock price: 57.00 pence
Year-to-date change: up sharply from 22.50p
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Genedrive